A Phase 1 Study of Acalabrutinib in Japanese Adult Patients with Advanced B-cell Malignancies

Trial Identifier: D8220C00001
Sponsor: AstraZeneca
NCTID:: NCT03198650
Start Date: June 2017
Primary Completion Date: December 2024
Study Completion Date: December 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Chiba-shi, Japan, 260-8717
Japan Chuo-ku, Japan, 104-0045
Japan Fukuoka-shi, Japan, 812-8582
Japan Isehara-shi, Japan, 259-1193
Japan Izumo-shi, Japan, 693-8501
Japan Matsuyama-shi, Japan, 791-0280
Japan Nagoya-shi, Japan, 464-8681
Japan Nagoya-shi, Japan, 460-0001
Japan Niigata-shi, Japan, 951-8520
Japan Okayama-shi, Japan, 700-8558
Japan Sapporo-shi, Japan, 060-8638
Japan Sendai-shi, Japan, 980-8574
Japan Shimotsuke-shi, Japan, 329-0498
Japan Suita-shi, Japan, 565-0871